Predicting in vivo drug interactions from in vitro drug discovery data
Top Cited Papers
- 1 October 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 4 (10) , 825-833
- https://doi.org/10.1038/nrd1851
Abstract
In vitro screening for drugs that inhibit cytochrome P450 enzymes is well established as a means for predicting potential metabolism-mediated drug interactions in vivo. Given that these predictions are based on enzyme kinetic parameters observed from in vitro experiments, the miscalculation of the inhibitory potency of a compound can lead to an inaccurate prediction of an in vivo drug interaction, potentially precluding a safe drug from advancing in development or allowing a potent inhibitor to 'slip' into the patient population. Here, we describe the principles underlying the generation of in vitro drug metabolism data and highlight commonly encountered uncertainties and sources of bias and error that can affect extrapolation of drug-drug interaction information to the clinical setting.Keywords
This publication has 78 references indexed in Scilit:
- A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in JapanJournal of Clinical Pharmacy & Therapeutics, 2005
- DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOSDrug Metabolism and Disposition, 2004
- Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugsThe Lancet Neurology, 2003
- Timing of New Black Box Warnings and Withdrawals for Prescription MedicationsJAMA, 2002
- Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymesDrug Metabolism Reviews, 2002
- Adverse drug reactions: definitions, diagnosis, and managementThe Lancet, 2000
- The Safety of Newly Approved MedicinesPublished by American Medical Association (AMA) ,1999
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998
- Selective Serotonin Reuptake Inhibitors and CNS Drug InteractionsClinical Pharmacokinetics, 1997
- Role of Cytochrome P450 Enzymes in Drug-Drug InteractionsPublished by Elsevier ,1997